Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
26/08/2026 07:53
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million Aug 26 (Reuters) - Biohaven BHVN.N has entered into a licensing agreement with South Korean drug maker SK Biopharmaceuticals 326030.KS for Biohaven's epilepsy drug platform, including Opakalim, for up to $795 million, the companies said in a statement on Wednesday.
(Reporting by Anusha Shah in Bengaluru; Editing by Sonia Cheema)
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker